Breaking News Instant updates and real-time market news.

MNTA

Momenta

$19.00

-0.05 (-0.26%)

08:08
02/17/17
02/17
08:08
02/17/17
08:08

Momenta announces HSR clearance for agreement with CSL

Momenta Pharmaceuticals announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the collaboration and license agreement with CSL to develop Fc multimer programs, including M230, executed by the company on January 5. With the termination of the applicable waiting period under the HSR Act, the collaboration and license agreement with CSL is effective as of February 17. Under the license agreement, CSL will pay Momenta a $50M upfront cash payment within 30 days of the effective date.

  • 21

    Feb

MNTA Momenta
$19.00

-0.05 (-0.26%)

01/31/17
STFL
01/31/17
NO CHANGE
STFL
Momenta price target raised to $30 from $20 at Stifel
Stifel analyst Thomas Shrader raised his price target on Momenta (MNTA) after a federal court invalidated Teva's (TEVA) Copaxone patents. The analyst says that there is now a 67% chance that Sandoz and Momenta will be able to access the Copaxone market, up from 50% previously. He keeps a Buy rating on Momenta.
01/31/17
LEHM
01/31/17
NO CHANGE
Target $38
LEHM
Equal Weight
Teva price target lowered to $38 from $46 at Barclays
Barclays analyst Douglas Tsao lowered his price target for Teva Pharmaceutical (TEVA) to $38 saying he sees an increased likelihood of Momenta (MNTA)/Sandoz launching a generic version of the company's Copaxone 40mg in the near term following last night's U.S. District Court decision ruling in favor of the generics. Momenta still needs FDA approval, but that could come as early as today, Tsao tells investors in a research note. Teva will likely seek an injunction to block an at-risk launch, but that is unlikely to be granted, the analyst contends. He does not believe Teva's additional patents will block generics. The analyst thinks Teva's earnings per share are likely to fall below $5.00. Tsao keeps an Equal Weight rating on the shares. Teva in pre-market trading is down $2.37 to $32.15. Momenta is up $1.25 to $16.35.
01/31/17
FBCO
01/31/17
NO CHANGE
Target $41
FBCO
Outperform
Teva patents loss another step toward generic competition, says Credit Suisse
Credit Suisse analyst Vamil Divan notes that the long-awaited decision from the U.S. District Court on four Orange Book listed patents for the 40mg/mL dose of Copaxone went against Teva (TEVA), representing another step toward the entry of generic versions into the U.S. market. The analyst expects Novartis (NVS)/Momenta (MNTA) and potentially one other competitor to launch later this year and lead to pricing pressure on the brand, while the volume impact will likely take a little longer based on the relatively slow initial uptake from Glatopa, a generic version of Copaxone 20mg/mL. He reiterates an Outperform rating and $41 price target on Teva's shares.
01/31/17
LEER
01/31/17
NO CHANGE
Target $20
LEER
Outperform
Teva patent ruling reduces barriers to a Momenta generic launch, says Leerink
Leerink analyst Jason Gerberry says the pro-generic ruling by the federal district court in Teva's (TEVA) Copaxone patent case further reduces the barriers to a Momenta (MNTA)/Novartis (NVS) generic launch in 2017. The analyst now assigns a higher likelihood to a Momenta this year, with a 90% probability. Moreover, Gerberry believes that among the five litigants in the Copaxone 40mg litigation, Momenta is "best positioned" to secure generic approval as it was the only entity to demonstrate bioequivalence to Copaxone's active ingredient. He reiterated an Outperform rating on Momenta's stock, and raised his price target on the shares to $20 from $19.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$255.48

-0.08 (-0.03%)

, JPM

JPMorgan

$104.66

-0.85 (-0.81%)

07:19
12/15/17
12/15
07:19
12/15/17
07:19
Periodicals
London-based investment banks to face tighter EU control, Reuters reports »

Large London-based…

GS

Goldman Sachs

$255.48

-0.08 (-0.03%)

JPM

JPMorgan

$104.66

-0.85 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:19
12/15/17
12/15
07:19
12/15/17
07:19
Upgrade
Criteo rating change  »

Criteo upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

07:15
12/15/17
12/15
07:15
12/15/17
07:15
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

07:14
12/15/17
12/15
07:14
12/15/17
07:14
Initiation
Rigel Pharmaceuticals initiated  »

Cantor sees FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:12
12/15/17
12/15
07:12
12/15/17
07:12
Downgrade
Criteo rating change  »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

07:11
12/15/17
12/15
07:11
12/15/17
07:11
Recommendations
Oracle analyst commentary  »

Oracle business momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$22.60

2.28 (11.22%)

07:10
12/15/17
12/15
07:10
12/15/17
07:10
Hot Stocks
Innovative Industrial Properties raises quarterly dividend to 25c per share »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$42.96

-0.72 (-1.65%)

07:08
12/15/17
12/15
07:08
12/15/17
07:08
Recommendations
Hologic analyst commentary  »

Hologic positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:07
12/15/17
12/15
07:07
12/15/17
07:07
Earnings
Performance Food Group sees FY18 adjusted EPS up 13%-18% »

For fiscal 2018, PFG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

TYME

Tyme Technologies

$3.30

0.05 (1.54%)

07:05
12/15/17
12/15
07:05
12/15/17
07:05
Initiation
Tyme Technologies initiated  »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

, SNY

Sanofi

$43.09

-0.83 (-1.89%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Alnylam announces lift of FDA clinical hold on Fitusiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

SNY

Sanofi

$43.09

-0.83 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

, UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Upgrade
Under Armour; also tag UAA, Under Armour; also tag UA rating change  »

Under Armour upgraded to…

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBA

Ritchie Bros.

$28.69

0.3 (1.06%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Ritchie Bros. sess $50M+ of equipment in final Fort Worth, TX auction of 2017 »

This week Ritchie Bros.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$43.09

-0.83 (-1.89%)

, ALNY

Alnylam

$123.66

-1.2 (-0.96%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Sanofi says FDA lifts clinical hold on fitusiran »

Sanofi Genzyme, the…

SNY

Sanofi

$43.09

-0.83 (-1.89%)

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

CROX

Crocs

$10.94

-0.34 (-3.01%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Upgrade
Crocs rating change  »

Crocs upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

ESNC

EnSync

$0.44

0.0663 (17.79%)

, CHTR

Charter

$328.68

-0.32 (-0.10%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
EnSync: Spectrum solar plus storage project commissioned in Hawaii »

EnSync (ESNC) announces…

ESNC

EnSync

$0.44

0.0663 (17.79%)

CHTR

Charter

$328.68

-0.32 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Performance Food Group appoints Jim Hope as CFO »

Performance Food Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

07:02
12/15/17
12/15
07:02
12/15/17
07:02
Hot Stocks
Aclaris Therapeutics receives FDA approval for Eskata topical solution, 40% »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

AER

AerCap

$52.12

-0.46 (-0.87%)

07:01
12/15/17
12/15
07:01
12/15/17
07:01
Recommendations
AerCap analyst commentary  »

AerCap book value can hit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$37.30

-0.75 (-1.97%)

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Recommendations
Q2 Holdings analyst commentary  »

Q2 Holdings has strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$6.82

-0.2 (-2.85%)

06:59
12/15/17
12/15
06:59
12/15/17
06:59
Downgrade
Fitbit rating change  »

Fitbit downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,174.80

10.61 (0.91%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Periodicals
Luxembourg appeals EU order to recover tax from Amazon, Reuters reports »

Luxembourg is appealing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Aclaris Therapeutics »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

GDX

Market Vector Gold Miners

$22.07

-0.09 (-0.41%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.